Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New shot aims to ease stubborn nerve pain

NCT ID NCT06091020

Symptom relief Sponsor: Merz Therapeutics GmbH Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether NT 201 injections can reduce pain in adults with long-term nerve pain caused by shingles or a nerve injury. 123 people received either NT 201 or a placebo shot, and researchers tracked their pain levels over 20 weeks. The goal was to see if the treatment safely lowers pain intensity better than a placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

123 people

The number who actually took part.

Started

Nov 2023

Finished

Jul 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Chronic peripheral neuropathic pain that persists for at least 6 months by the time of the screening visit and is plausibly related to either an episode of herpes zoster or a peripheral nerve injury (caused by surgery or mechanical trauma). * Documented diagnosis of either chronic neuropathic pain after peripheral nerve injury (i.e., postsurgical/post-traumatic neuropathic pain) or postherpetic neuralgia with at least probable level of certainty according to the NeuPSIG/IASP (Neuropathic Pain Special Interest Group / International Association on the Study of Pain) grading system. * A score of at least 4 out of 10 points on the Neuropathic Pain 4 Questions (DN4) questionnaire. Exclusion Criteria: * Complex Regional Pain Syndrome Type 1 and Type 2. * Any other painful condition or disease that requires treatment (only mild to moderate episodic migraine treated with triptans and/or non-steroidal anti- inflammatory drugs (NSAIDs), if any, is acceptable). * Postsurgical/post-traumatic neuropathic pain due to amputation and/or phantom limb pain.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Moderate to severe chronic peripheral neuropathic pain (PNP) due to postherpetic neuralgia (PHN) or peripheral nerve injury are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Neuralgia, Postherpetic Peripheral Nerve Injuries postherpetic neuralgia traumatic neuropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Moderate to severe chronic peripheral neuropathic pain (PNP) due to postherpetic neuralgia (PHN) or peripheral nerve injury

Contacts and locations

Locations

  • Merz Investigational Site #0330065

    Limoges, 87042, France

  • Merz Investigational Site #0330066

    Boulogne-Billancourt, 92100, France

  • Merz Investigational Site #0330067

    Nîmes, 30029, France

  • Merz Investigational Site #0340041

    L'Hospitalet de Llobregat, 08907, Spain

  • Merz Investigational Site #0340042

    Seville, 41013, Spain

  • Merz Investigational Site #0340043

    Barcelona, 08035, Spain

  • Merz Investigational Site #0340044

    Córdoba, 14029, Spain

  • Merz Investigational Site #0360020

    Budapest, H-1122, Hungary

  • Merz Investigational Site #0360021

    Budapest, H-1036, Hungary

  • Merz Investigational Site #0360022

    Budapest, H-1145, Hungary

  • Merz Investigational Site #0480059

    Krakow, 30-539, Poland

  • Merz Investigational Site #0480107

    Warsaw, 02-672, Poland

  • Merz Investigational Site #0480108

    Wroclaw, 50-381, Poland

  • Merz Investigational Site #0480109

    Warsaw, 00-710, Poland

  • Merz Investigational Site #0480110

    Poznan, 60-702, Poland

  • Merz Investigational Site #0480111

    Katowice, 40-040, Poland

  • Merz Investigational Site #0480112

    Gdynia, 81-537, Poland

  • Merz Investigational Site #0480113

    Częstochowa, 42-202, Poland

  • Merz Investigational Site #0480114

    Lublin, 20-078, Poland

  • Merz Investigational Site #0480115

    Katowice, 40-282, Poland

  • Merz Investigational Site #0490174

    Essen, 45147, Germany

  • Merz Investigational Site #0490219

    Leipzig, 04103, Germany

  • Merz Investigational Site #0490386

    Frankfurt, 60313, Germany

  • Merz Investigational Site #0490387

    Westerstede, 26655, Germany

  • Merz Investigational Site #0490388

    Kiel, 24105, Germany

  • Merz Investigational Site #0490389

    Hamburg, 20095, Germany

  • Merz Investigational Site #3590002

    Sofia, 1784, Bulgaria

  • Merz Investigational Site #3590003

    Veliko Tarnovo, 5000, Bulgaria

  • Merz Investigational Site #3590004

    Plovdiv, 4000, Bulgaria

  • Merz Investigational Site #3590005

    Sofia, 1606, Bulgaria

  • Merz Investigational Site #3590006

    Sofia, 1113, Bulgaria

More trials for these conditions

Other studies related to the condition(s) this trial covers.